Cell Source, Inc.: peers
Cell Source, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Cell Source, Inc., Zivo Bioscience Inc., Reviva Pharmaceuticals Holdings, Inc., Sigyn Therapeutics, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Cell Source, Inc.base CLCS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Zivo Bioscience Inc. ZIVO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Karyopharm Therapeutics Inc. KPTI · 🇺🇸 US Percentile in Healthcare Percentile in USA | Seres Therapeutics, Inc. MCRB · 🇺🇸 US Percentile in Healthcare Percentile in USA | Black Hawk Acquisition Corporation BKHA · 🇺🇸 US Percentile in Healthcare Percentile in USA | Aytu Bioscience AYTU · 🇺🇸 US Percentile in Healthcare Percentile in USA | Reviva Pharmaceuticals Holdings, Inc. RVPH · 🇺🇸 US Percentile in Healthcare Percentile in USA | Sigyn Therapeutics, Inc. SIGY · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $20 Mlast known, Dec 25, 2022 · Market dataLast known value: no current one3rd of 8 | $20 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one3rd of 8 | $20 MOct 30, 2026 · Market data5th of 8 | $20 MOct 30, 2026 · Market data6th of 8 | $20 MOct 30, 2026 · Market data7th of 8 | $21 MOct 26, 2026 · Market data2nd of 8 | $21 Mlast known, Mar 8, 2026 · Market dataLast known value: no current one1st of 8 | $19 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one8th of 8 | $20 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $0 MFY2024 · SEC4th of 4 | $146 MFY2025 · SEC1st of 4 | $1 MFY2025 · SEC3rd of 4 | —— | $58 MFY2026 · SEC2nd of 4 | —— | —— | $29 M4 ranked |
| Net income (Higher is better) | $-5 MFY2024 · SEC4th of 8 | $-13 MFY2024 · SEC5th of 8 | $-196 MFY2025 · SEC8th of 8 | $6 MFY2025 · SEC1st of 8 | $1 MFY2025 · SEC2nd of 8 | $-14 MFY2026 · SEC6th of 8 | $-20 MFY2025 · SEC7th of 8 | $-3 MFY2024 · SEC3rd of 8 | $-9 M8 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | 442As on 2021 · Profile1st of 2 | 333As on 2021 · Profile2nd of 2 | —— | —— | —— | —— | 3882 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | +0.6%FY2025 · SEC1st of 227th31st | ———— | ———— | -13.3%FY2026 · SEC2nd of 213th9th | ———— | ———— | -6.3%2 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | -2.4%FY2025 · SEC1st of 221st25th | ———— | ———— | -18.8%FY2026 · SEC2nd of 28th4th | ———— | ———— | -10.6%2 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | 64.0%FY2026 · SEConly one with it58th78th | ———— | ———— | 64.0%— |
| Operating margin (Higher is better) | ———— | ———— | -62.1%FY2025 · SEC2nd of 229th14th | ———— | ———— | -14.4%FY2026 · SEC1st of 244th24th | ———— | ———— | -38.3%2 ranked |
| Net margin (Higher is better) | ———— | ———— | -134.2%FY2025 · SEC2nd of 220th8th | ———— | ———— | -24.8%FY2026 · SEC1st of 240th20th | ———— | ———— | -79.5%2 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | -51.6%FY2025 · SEC2nd of 227th12th | ———— | ———— | 5.7%FY2026 · SEC1st of 263rd56th | ———— | ———— | -23.0%2 ranked |
| Return on equity (Higher is better) | ———— | ———— | ———— | 19.7%FY2025 · SEC1st of 390th84th | ———— | -52.5%FY2026 · SEC2nd of 342nd18th | -419.9%FY2025 · SEC3rd of 32nd1st | ———— | -52.5%3 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | ———— | 3.5×price Oct 30, 2026 · Market data2nd of 24th3rd | 14.9×price Oct 30, 2026 · Market data1st of 220th37th | ———— | ———— | ———— | 9.2×2 ranked |
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | 0.1×price Oct 30, 2026 · Market data3rd of 31st4th | 25.2×price Oct 30, 2026 · Market data1st of 386th95th | ———— | 0.4×price Oct 26, 2026 · Market data2nd of 36th11th | ———— | ———— | 0.4×3 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | 0.5×price Oct 30, 2026 · Market data2nd of 26th6th | ———— | 0.6×price Oct 26, 2026 · Market data1st of 29th9th | ———— | ———— | 0.5×2 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | 4.4%price Oct 30, 2026 · Market data2nd of 284th62nd | ———— | 15.7%price Oct 26, 2026 · Market data1st of 297th94th | ———— | ———— | 10.0%2 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | ———— | 0.3×FY2026 · SEConly one with it36th27th | ———— | ———— | 0.3×— |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | -46.0×FY2025 · SEC2nd of 221st10th | -4.4×FY2026 · SEC1st of 257th31st | ———— | ———— | -25.2×2 ranked |
| Piotroski F-score (Higher is better) | —— | —— | —— | —— | —— | 4 of 9FY2026 · SEConly one with it | —— | —— | 4.0 of 9— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 0 of 6FY2024 · Scorecard6th of 8 | 0 of 7FY2024 · Scorecard6th of 8 | 5 of 18FY2025 · Scorecard4th of 8 | 8 of 14FY2025 · Scorecard1st of 8 | 3 of 6FY2025 · Scorecard2nd of 8 | 9 of 21FY2026 · Scorecard3rd of 8 | 1 of 6FY2025 · Scorecard5th of 8 | 0 of 7FY2024 · Scorecard6th of 8 | 22% passed8 ranked |
| Valuation checks (Higher is better) | —— | —— | 1 of 4FY2025 · Scorecard4th of 4 | 3 of 5FY2025 · Scorecard2nd of 4 | 2 of 3FY2025 · Scorecard1st of 4 | 3 of 5FY2026 · Scorecard2nd of 4 | —— | —— | 60% passed4 ranked |
| Growth checks (Higher is better) | 0 of 2FY2024 · Scorecard4th of 7 | 0 of 2FY2024 · Scorecard4th of 7 | 2 of 6FY2025 · Scorecard2nd of 7 | 2 of 2FY2025 · Scorecard1st of 7 | —— | 1 of 5FY2026 · Scorecard3rd of 7 | 0 of 1FY2025 · Scorecard4th of 7 | 0 of 2FY2024 · Scorecard4th of 7 | 0% passed7 ranked |
| Profitability checks (Higher is better) | 0 of 2FY2024 · Scorecard5th of 8 | 0 of 2FY2024 · Scorecard5th of 8 | 1 of 4FY2025 · Scorecard4th of 8 | 2 of 3FY2025 · Scorecard2nd of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 2 of 5FY2026 · Scorecard3rd of 8 | 0 of 3FY2025 · Scorecard5th of 8 | 0 of 2FY2024 · Scorecard5th of 8 | 13% passed8 ranked |
| Financial health checks (Higher is better) | 0 of 1FY2024 · Scorecard5th of 8 | 0 of 2FY2024 · Scorecard5th of 8 | 1 of 3FY2025 · Scorecard3rd of 8 | 1 of 3FY2025 · Scorecard3rd of 8 | 0 of 2FY2025 · Scorecard5th of 8 | 3 of 6FY2026 · Scorecard1st of 8 | 1 of 2FY2025 · Scorecard1st of 8 | 0 of 2FY2024 · Scorecard5th of 8 | 17% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2024 · Scorecard1st of 5 | 0 of 1FY2024 · Scorecard1st of 5 | 0 of 1FY2025 · Scorecard1st of 5 | 0 of 1FY2025 · Scorecard1st of 5 | —— | —— | —— | 0 of 1FY2024 · Scorecard1st of 5 | 0% passed5 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 0.1%2025-Q4 · 13F5th of 6 | 76.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 6 | 23.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6 | 34.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 6 | 34.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 6 | 0.1%2026-Q2 · 13F6th of 6 | —— | 28.5%6 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 32025-Q4 · 13F6th of 6 | 922026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 6 | 402026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 6 | 172026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6 | 362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 6 | 52026-Q2 · 13F5th of 6 | —— | 276 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | +0.0 pp2025-Q4 against 2025-Q3 · 13F4th of 6 | +16.5 pp2026-Q2 against 2026-Q1 · 13F1st of 6 | -1.2 pp2026-Q2 against 2026-Q1 · 13F5th of 6 | +8.6 pp2026-Q2 against 2026-Q1 · 13F3rd of 6 | +8.9 pp2026-Q2 against 2026-Q1 · 13F2nd of 6 | -22.7 pp2026-Q2 against 2026-Q1 · 13F6th of 6 | —— | +4.3 pp6 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Cell Source, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Zivo Bioscience Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Karyopharm Therapeutics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Seres Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Black Hawk Acquisition Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Aytu Bioscience: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Reviva Pharmaceuticals Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Sigyn Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Cell Source, Inc. | — | — | — |
| Zivo Bioscience Inc. | — | — | — |
| Karyopharm Therapeutics Inc. | -62.1%FY2025 | 29th percentile in Healthcaremedian -7.7%, 674 companies | 14th percentile in USAmedian 3.5%, 2,594 companies |
| Seres Therapeutics, Inc. | — | — | — |
| Black Hawk Acquisition Corporation | — | — | — |
| Aytu Bioscience | -14.4%FY2026 | 44th percentile in Healthcaremedian -7.7%, 674 companies | 24th percentile in USAmedian 3.5%, 2,594 companies |
| Reviva Pharmaceuticals Holdings, Inc. | — | — | — |
| Sigyn Therapeutics, Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Cell Source, Inc. | Zivo Bioscience Inc. | Karyopharm Therapeutics Inc. | Seres Therapeutics, Inc. | Black Hawk Acquisition Corporation | Aytu Bioscience | Reviva Pharmaceuticals Holdings, Inc. | Sigyn Therapeutics, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2026 | — | — | — | — | — | $58 MSEC | — | — |
| 2025 | — | — | $146 MSEC1st | $1 MSEC3rd | — | $66 MSEC2nd | — | — |
| 2024 | — | $0 MSEC3rd | $145 MSEC1st | — | — | $65 MSEC2nd | — | — |
| 2023 | — | $0 MSEC3rd | $146 MSEC1st | — | — | $107 MSEC2nd | — | — |
| 2022 | — | — | $157 MSEC1st | $7 MSEC3rd | — | $97 MSEC2nd | — | — |
| 2021 | — | — | $210 MSEC1st | $145 MSEC2nd | — | $66 MSEC3rd | — | — |
| 2020 | — | $0 MSEC4th | $108 MSEC1st | $33 MSEC2nd | — | $28 MSEC3rd | — | — |
| 2019 | — | — | $41 MSEC1st | $35 MSEC2nd | — | $7 MSEC3rd | — | $0 MSEC4th |
| 2018 | — | — | $30 MSEC1st | $28 MSEC2nd | — | $4 MSEC3rd | — | $0 MSEC4th |
| 2017 | — | — | $2 MSEC3rd | $32 MSEC1st | — | $3 MSEC2nd | — | $0 MSEC4th |
| 2016 | — | — | $0 MSEC3rd | $22 MSEC1st | — | $3 MSEC2nd | — | — |
| 2015 | — | — | $0 MSEC2nd | — | — | $0 MSEC1st | — | $0 MSEC3rd |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Cell Source, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Zivo Bioscience Inc.ZIVO · 🇺🇸 USASame industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $20 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2024)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Karyopharm Therapeutics Inc.KPTI · 🇺🇸 USASame industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $20 M (Oct 30, 2026) · revenue $146 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Seres Therapeutics, Inc.MCRB · 🇺🇸 USASame industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $20 M (Oct 30, 2026) · revenue $1 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Black Hawk Acquisition CorporationBKHA · 🇺🇸 USASame industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $20 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Aytu BioscienceAYTU · 🇺🇸 USASame industry: Biotechnology · Similar size: $21 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $21 M (Oct 26, 2026) · revenue $58 M (year to June 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Reviva Pharmaceuticals Holdings, Inc.RVPH · 🇺🇸 USASame industry: Biotechnology · Similar size: $21 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $21 M (last known, Mar 8, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Sigyn Therapeutics, Inc.SIGY · 🇺🇸 USASame industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $19 M (last known, Jan 7, 2022)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Cocrystal Pharma, Inc.COCP · 🇺🇸 USASame industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $19 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Senti Biosciences, Inc.SNTI · 🇺🇸 USASame industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $19 M (Oct 30, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- BeyondSpring Inc.BYSI · 🇺🇸 USASame industry: Biotechnology · Similar size: $22 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $22 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Context Therapeutics Inc.CNTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $22 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $22 M (Oct 27, 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Lipocine Inc.LPCN · 🇺🇸 USASame industry: Biotechnology · Similar size: $18 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $18 M (Oct 13, 2026) · revenue $2 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.